GLP-1 Products

Mounjaro® (tirzepatide) is a prescription medication developed by Eli Lilly, approved by the FDA in May 2022 for improving blood sugar control in adults with type 2 diabetes. It is administered once weekly via subcutaneous injection. Tirzepatide functions as a dual agonist of the GLP-1 and GIP receptors, enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite.

Ozempic, aka Semaglutide, is an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon-like peptide-1, modified with a side chain. It can be administered by subcutaneous injection or taken orally.

Rybelsus (semaglutide) is an oral medication used to improve blood sugar control in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists, which help lower blood sugar by stimulating insulin release when glucose levels are high, reducing glucose production by the liver, and slowing stomach emptying to reduce appetite. Unlike other GLP-1 drugs that require injections, Rybelsus is the first GLP-1 receptor agonist available as a once-daily oral tablet, making it a convenient option for people who prefer pills over injections.

Trulicity, also known as dulaglutide, is a GLP-1 receptor agonist medication prescribed to manage type 2 diabetes and reduce cardiovascular risks in certain adults. It works by mimicking a natural hormone that regulates blood sugar. Trulicity is administered weekly via subcutaneous injection.

Victoza (liraglutide) is a once-daily injectable medication used to improve blood sugar control in adults with type 2 diabetes. It belongs to the class of drugs called GLP-1 receptor agonists. Victoza works by stimulating insulin secretion when blood sugar is high, reducing the amount of glucose produced by the liver, slowing gastric emptying, and decreasing appetite. In addition to blood sugar control, Victoza has been shown to reduce the risk of major cardiovascular events, such as heart attack or stroke, in people with type 2 diabetes who have established heart disease or are at high risk.

Wegovy (semaglutide) is a prescription medication used to manage weight in adults and children (12 years and older) with obesity or overweight with at least one weight-related medical condition. It is a glucagon-like peptide-1 (GLP-1) receptor agonist.

Zepbound is a once-weekly injectable prescription medication approved for chronic weight management in adults with obesity or overweight and at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol). It contains tirzepatide, a dual GIP and GLP-1 receptor agonist that mimics two naturally occurring hormones involved in appetite regulation and blood sugar control. Originally developed as a treatment for type 2 diabetes under the name Mounjaro, tirzepatide was later approved for weight loss due to its superior efficacy in clinical trials. Zepbound works by slowing gastric emptying, enhancing insulin sensitivity, and reducing appetite, helping individuals lose significant weight and improve metabolic health.